Download PDF
Dtsch Med Wochenschr 2012; 137(49): 2567-2570
DOI: 10.1055/s-0032-1327332
Nephrologie | Commentary
Nephrologie, Transplantationsmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Dialysetherapie und Nierentransplantation

Update 2012Dialysis and renal transplantationUpdate 2012
W. Riegel
1   Medizinische Klinik III, Klinikum Darmstadt
,
B. Krüger
2   V. Medizinische Klinik, Universitätsklinikum Mannheim
,
P. Schnülle
3   Nierenzentrum Weinheim
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Peritonealdialyse - Hygiene - Sirolimus - Betalacept - mesenchymale Stammzellen

Keywords

peritoneal dialysis - hygiene - sirolimus - betalacept - mesenchymal stem cells
 

  • Literatur

  • 1 Campbell SB, Walker R, Tai SS et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156
    CrossrefPubMedGoogle Scholar
  • 2 Cnossen TT, Kooman JP, Krepel HP et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. NephrolDial Transplant 2012; 27: 2794-2799
    PubMedGoogle Scholar
  • 3 Dalrymple LS, Katz R, Kestenbaum B et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59: 356-363
    CrossrefPubMedGoogle Scholar
  • 4 Euvrard S, Morelon E, Rostaing L et al. TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339
    CrossrefPubMedGoogle Scholar
  • 5 James MT, Quan H, Tonelli M et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54: 24-32
    CrossrefPubMedGoogle Scholar
  • 6 Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326
    CrossrefPubMedGoogle Scholar
  • 7 Núñez J, González M, Miñana G et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 2012; 14: 540-548
    CrossrefPubMedGoogle Scholar
  • 8 Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639
    CrossrefPubMedGoogle Scholar
  • 9 Sens F, Schott-Pethelaz AM, Labeeuw M et al. on behalf of the REIN Registry. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. Kidney Int 2011; 80, 970-977
    PubMedGoogle Scholar
  • 10 Tan J, Wu W, Xu X et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants. JAMA 2012; 307: 1169-1177
    CrossrefPubMedGoogle Scholar
  • 11 Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217
    CrossrefPubMedGoogle Scholar